Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Phosphate binders are crucial to the control of elevated phosphate levels in patients with
chronic kidney disease. With the new formulation of granules the pill burden of patients is
sought to be reduced.
This study is about efficacy and safety of the new drug formulation and compares it to the
"old" formulation which are film-coated tablets.